Prandial insulin analog now available

March 6, 2006

Sanofi-Aventis has announced that Apidra (insulin glulisine [rDNA origin] injection) is now available for the control of hyperglycemia in adult patients with Type 1 and Type 2 diabetes. Apidra is a rapid-acting insulin with an onset and duration of action that are faster and shorter than those of regular human insulin.

Prandial insulin analog now available

Sanofi-Aventis has announced that Apidra (insulin glulisine [rDNA origin] injection) is now available for the control of hyperglycemia in adult patients with Type 1 and Type 2 diabetes. Apidra is a rapid-acting insulin with an onset and duration of action that are faster and shorter than those of regular human insulin. According to the company, the new insulin should be used in regimens that include longer-acting or basal insulins and should be administered within 15 minutes before or within 20 minutes after starting a meal. The manufacturer has also announced the availability of Apidra cartridges for use with the reusable OptiClik injection pen, also approved for use with Lantus (insulin glargine [rDNA origin] injection), the company's once-daily basal insulin. Apidra received FDA approval in April 2004.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.